Fig. 3From: The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancersMechanisms of DDRi and ICB affecting PD‐L1 expression and TME in tumors with DDR deficiency. DNA damage amplified by DDRi activates cGAS/STING, DNA damage response, and neoantigen pathway, inducing PD-L1 expression, pro-inflammatory cytokines release and CTLs infiltration while reducing Tregs and exhausted T cells, which combines with ICB, leading to immune activation and immunogenic cell death. Cyclic GMP‐AMP synthase (cGAS); stimulator of interferon genes (STING); double-strand breaks (DSB); homologous recombination (HR); microsatellite instability (MSI); mismatch repair deficiency (MMRd); homologous recombination deficiency (HRD); breast cancer 1/2 (BRCA1/2); DNA damage response (DDR); T cell receptor (TCR); programmed death‐ligand 1 (PD‐L1); programmed death‐1(PD-1); cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4); cytotoxic CD8+ T cells (CTLs); tumor-necrosis factorα (TNFα); interferon γ(IFN γ); interferon alpha/beta receptor (IFNAR); interferon regulatory factors (IRFs); regulatory T cells (Tregs); immune checkpoint blockade (ICB); granulocytic/monocytic myeloid-derived suppressor cells (g/mMDSCs); poly-ADP-ribose polymerase (PARP); ataxia telangiectasia and Rad3-related protein (ATR); checkpoint kinase 1 (CHK1); effector T-cells (Teff)Back to article page